...
search icon
rcus-img

Arcus Biosciences Inc, Common Stock

RCUS

NYQ

$9.855

-$0.12

(-1.2%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$976.26M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
732.38K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.83
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$6.5 L
$18.98 H
$9.855

About Arcus Biosciences Inc, Common Stock

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRCUSSectorS&P500
1-Week Return6.83%1.08%1.06%
1-Month Return18.96%1.11%6.17%
3-Month Return4.68%-9.16%6.82%
6-Month Return-43.62%-7.29%-0.94%
1-Year Return-38.78%-8.72%11.83%
3-Year Return-57.43%5.18%49.19%
5-Year Return-66.69%30.45%86.63%
10-Year Return-42.06%81.41%188.21%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue77.52M382.88M112.00M117.00M258.00M[{"date":"2020-12-31","value":20.25,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":29.25,"profit":true},{"date":"2023-12-31","value":30.56,"profit":true},{"date":"2024-12-31","value":67.38,"profit":true}]
Cost of Revenue159.00M7.06M14.00M340.00M10.00M[{"date":"2020-12-31","value":46.76,"profit":true},{"date":"2021-12-31","value":2.08,"profit":true},{"date":"2022-12-31","value":4.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":2.94,"profit":true}]
Gross Profit(81.48M)375.82M98.00M(223.00M)248.00M[{"date":"2020-12-31","value":-21.68,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":26.08,"profit":true},{"date":"2023-12-31","value":-59.34,"profit":false},{"date":"2024-12-31","value":65.99,"profit":true}]
Gross Margin(105.12%)98.16%87.50%(190.60%)96.12%[{"date":"2020-12-31","value":-107.09,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":89.14,"profit":true},{"date":"2023-12-31","value":-194.18,"profit":false},{"date":"2024-12-31","value":97.93,"profit":true}]
Operating Expenses201.75M328.63M392.00M457.00M588.00M[{"date":"2020-12-31","value":34.31,"profit":true},{"date":"2021-12-31","value":55.89,"profit":true},{"date":"2022-12-31","value":66.67,"profit":true},{"date":"2023-12-31","value":77.72,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(124.23M)54.25M(280.00M)(340.00M)(330.00M)[{"date":"2020-12-31","value":-229.01,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-516.15,"profit":false},{"date":"2023-12-31","value":-626.75,"profit":false},{"date":"2024-12-31","value":-608.32,"profit":false}]
Total Non-Operating Income/Expense2.75M794.00K28.00M78.00M95.00M[{"date":"2020-12-31","value":2.9,"profit":true},{"date":"2021-12-31","value":0.84,"profit":true},{"date":"2022-12-31","value":29.47,"profit":true},{"date":"2023-12-31","value":82.11,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(122.86M)54.65M(266.00M)(301.00M)(283.00M)[{"date":"2020-12-31","value":-224.83,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-486.78,"profit":false},{"date":"2023-12-31","value":-550.83,"profit":false},{"date":"2024-12-31","value":-517.89,"profit":false}]
Income Taxes(6.18M)1.81M1.00M6.00M(1.00M)[{"date":"2020-12-31","value":-103.02,"profit":false},{"date":"2021-12-31","value":30.25,"profit":true},{"date":"2022-12-31","value":16.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":-16.67,"profit":false}]
Income After Taxes(116.68M)52.83M(267.00M)(307.00M)(282.00M)[{"date":"2020-12-31","value":-220.85,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-505.39,"profit":false},{"date":"2023-12-31","value":-581.11,"profit":false},{"date":"2024-12-31","value":-533.79,"profit":false}]
Income From Continuous Operations(122.86M)52.83M(267.00M)(307.00M)(284.00M)[{"date":"2020-12-31","value":-232.55,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-505.39,"profit":false},{"date":"2023-12-31","value":-581.11,"profit":false},{"date":"2024-12-31","value":-537.57,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(116.68M)53.00M(267.00M)(307.00M)(283.00M)[{"date":"2020-12-31","value":-220.15,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-503.77,"profit":false},{"date":"2023-12-31","value":-579.25,"profit":false},{"date":"2024-12-31","value":-533.96,"profit":false}]
EPS (Diluted)(2.35)0.43(3.72)(4.15)(3.10)[{"date":"2020-12-31","value":-546.51,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-865.12,"profit":false},{"date":"2023-12-31","value":-965.12,"profit":false},{"date":"2024-12-31","value":-720.93,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RCUS
Cash Ratio 5.19
Current Ratio 5.37

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RCUS
ROA (LTM) -22.25%
ROE (LTM) -63.17%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RCUS
Debt Ratio Lower is generally better. Negative is bad. 0.54
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.46

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RCUS
Trailing PE NM
Forward PE NM
P/S (TTM) 7.49
P/B 1.99
Price/FCF NM
EV/R 0.84
EV/Ebitda 3.96

FAQs

What is Arcus Biosciences Inc share price today?

Arcus Biosciences Inc (RCUS) share price today is $9.855

Can Indians buy Arcus Biosciences Inc shares?

Yes, Indians can buy shares of Arcus Biosciences Inc (RCUS) on Vested. To buy Arcus Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RCUS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Arcus Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Arcus Biosciences Inc (RCUS) via the Vested app. You can start investing in Arcus Biosciences Inc (RCUS) with a minimum investment of $1.

How to invest in Arcus Biosciences Inc shares from India?

You can invest in shares of Arcus Biosciences Inc (RCUS) via Vested in three simple steps:

  • Click on Sign Up or Invest in RCUS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Arcus Biosciences Inc shares
What is Arcus Biosciences Inc 52-week high and low stock price?

The 52-week high price of Arcus Biosciences Inc (RCUS) is $18.98. The 52-week low price of Arcus Biosciences Inc (RCUS) is $6.5.

What is Arcus Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Arcus Biosciences Inc (RCUS) is 1.99

What is the Market Cap of Arcus Biosciences Inc?

The market capitalization of Arcus Biosciences Inc (RCUS) is $976.26M

What is Arcus Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Arcus Biosciences Inc is RCUS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top